Among patients with stage III colon cancer, patients aged 70 or older were less tolerant of adjuvant oxaliplatin/flouropyrimidine therapy, in addition to having poorer relapse-free interval rates on the regimen, according to findings from a large subgroup analysis of the phase III TOSCA trial presented by Lonardi et al at the ESMO Virtual Congress 2020.
Nivolumab monotherapy showed high response and disease control rates in patients with pathogenic exonuclease domain POLE (edPOLE)-mutated, mismatch repair (MMR)-proficient advanced tumors containing confirmed pathogenic mutations, according to findings presented by Benoit J.C. Rousseau, MD, PhD, at the ESMO Virtual Congress 2020.
Findings from two meta-analyses designed to summarize quality-of-life data on patients receiving immune checkpoint inhibitor therapy for cancer were presented by Gonzalez et al at the ESMO Virtual Congress 2020. These meta-analyses found that patients receiving immune checkpoint inhibitors had better quality of life than patients receiving non–immune checkpoint inhibitor treatment.
At the 2020 Debates and Didactics in Hematology and Oncology Virtual Conference, Pamela Allen, MD, described recent trials on therapeutic approaches for Hodgkin lymphoma.
| 
In the phase IIa plasmaMATCH platform trial reported in The Lancet Oncology, Nicholas C. Turner, MD, and colleagues found that circulating tumor DNA (ctDNA) provided accurate genotyping that permitted selection of directed therapies in patients with advanced breast cancer.
In an exploratory analysis of the phase IIIb/IV CheckMate 153 trial published in the Journal of Clinical Oncology, David M. Waterhouse, MD, MPH, and colleagues found that continuing nivolumab beyond 1 year of treatment vs stopping at 1 year of treatment was associated with better outcomes in patients with previously treated advanced non–small cell lung cancer (NSCLC).
As reported in The New England Journal of Medicine by Reinhard Dummer, MD, and colleagues, 5-year follow-up of the phase III COMBI-AD trial has shown continued relapse-free survival benefit with adjuvant dabrafenib/trametinib vs placebo in patients with stage III melanoma and BRAF V600E or V600K mutations.
Long-term findings from the phase III CheckMate 238 study showed that nivolumab improved 4-year recurrence-free survival compared with ipilimumab in patients with resected stage IIIB to C or IV melanoma in the overall population as well as across subgroups of patients stratified by disease stage and PD-L1 expression levels. The findings were presented by Jeffrey Weber, MD, PhD, at the ESMO Virtual Congress 2020.
